Want to see IL:CANF full AI Analyst Report?
CANF Stock Chart & Stats
732.30
>-0.01(-4.76%)
At close: 4:00 PM EST
732.30
>-0.01(-4.76%)
Day’s Range― - ―
52-Week Range374.00 - 3,900.00
Previous CloseN/A
Volume13.23M
Average Volume (3M)1.04M
Market Cap
₪22.32M
Enterprise Value51.64
Total Cash (Recent Filing)₪8.54M
Total Debt (Recent Filing)₪71.00K
Price to Earnings (P/E)―
Beta-0.43
Next Earnings
Aug 27, 2026EPS Estimate
-50.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.30
Shares Outstanding4,285,093
10 Day Avg. Volume130,742
30 Day Avg. Volume1,039,800
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.77
Price to Sales (P/S)35.39
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet FlexibilityVery low leverage gives durable financial flexibility: with minimal debt the company can prioritize funding clinical programs or seek non-debt partnerships rather than servicing interest. This reduces short-term insolvency risk and lengthens runway options while clinical milestones are pursued.
High Gross Margins On Reported SalesExtremely high gross margins indicate that, if clinical assets reach commercialization or licensing, unit economics could be attractive. High margins support scalable profitability once R&D and selling costs are amortized and enable future margin expansion with modest revenue growth.
Focused Clinical-Stage PipelineA concentrated pipeline targeting a defined receptor class (A3AR) with two lead assets creates strategic focus and technical expertise. This specialization supports potential partnerships, licensing, or niche leadership in inflammatory and liver oncology indications over the medium term.
Bears Say
Very Small And Declining RevenuePersistently tiny and shrinking revenues mean the business lacks sustainable commercial income to fund operations. Over 2–6 months this undermines self-funding prospects, increases dependence on external capital, and limits ability to scale development without dilution or strategic deals.
Large And Worsening Operating / Net LossesDeepening operating and net losses erode equity and compress strategic options. Continued high losses force management to prioritize financing or cut programs, increasing dilution risk and potentially delaying or narrowing clinical development choices over the medium term.
Consistent Negative Cash GenerationOngoing negative operating and free cash flow indicates the company does not self-fund development and will need external financing or partnerships. Even with some 2025 improvement, persistent cash burn constrains runway and increases reliance on dilutive raises or non-dilutive deals.
Can Fite Bio News
CANF FAQ
What was Can-Fite BioPharma Ltd.’s price range in the past 12 months?
Can-Fite BioPharma Ltd. lowest stock price was 374.00 and its highest was 3900.00 in the past 12 months.
What is Can-Fite BioPharma Ltd.’s market cap?
Can-Fite BioPharma Ltd.’s market cap is ₪22.32M.
When is Can-Fite BioPharma Ltd.’s upcoming earnings report date?
Can-Fite BioPharma Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 36 days.
How were Can-Fite BioPharma Ltd.’s earnings last quarter?
Can-Fite BioPharma Ltd. released its earnings results on Mar 26, 2026. The company reported -910.186 earnings per share for the quarter, missing the consensus estimate of -21.344 by -888.841.
Is Can-Fite BioPharma Ltd. overvalued?
According to Wall Street analysts Can-Fite BioPharma Ltd.’s price is currently Overvalued.
Does Can-Fite BioPharma Ltd. pay dividends?
Can-Fite BioPharma Ltd. does not currently pay dividends.
What is Can-Fite BioPharma Ltd.’s EPS estimate?
Can-Fite BioPharma Ltd.’s EPS estimate is -50.31.
How many shares outstanding does Can-Fite BioPharma Ltd. have?
Can-Fite BioPharma Ltd. has 4,285,093 shares outstanding.
What happened to Can-Fite BioPharma Ltd.’s price movement after its last earnings report?
Can-Fite BioPharma Ltd. reported an EPS of -910.186 in its last earnings report, missing expectations of -21.344. Following the earnings report the stock price went down -0.719%.
Which hedge fund is a major shareholder of Can-Fite BioPharma Ltd.?
Currently, no hedge funds are holding shares in IL:CANF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutic agents. Its research and development efforts are concentrated on addressing conditions such as cancer, various liver inflammatory diseases, and erectile dysfunction. The company's lead investigational compound, Piclidenoson, has progressed through successful completion of its Phase III clinical trial for psoriasis and a Phase II clinical trial for COVID-19. Another promising candidate, Namodenoson, is presently undergoing a Phase III trial for hepatocellular carcinoma and a Phase IIb trial for non-alcoholic steatohepatitis. Furthermore, CF602 is in its pre-clinical phase, with potential application for erectile dysfunction. Beyond drug development, Can-Fite also creates a commercial predictive biomarker blood test kit specifically for A3AR. The company maintains strategic partnerships, including a licensing and collaboration agreement with CMS Medical for the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. A separate collaborative venture with Univo Pharmaceuticals focuses on identifying and jointly developing specific cannabis component formulations intended for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Founded in 1994 as Can-Fite Technologies Ltd., the company rebranded to Can-Fite BioPharma Ltd. in January 2001, and operates from its headquarters in Petah Tikva, Israel.